These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 15308883)

  • 41. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A; Giner V
    Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of angiotensin II type 1 receptor blocker on blood pressure variability and cardiovascular remodeling in hypertensive patients on chronic peritoneal dialysis.
    Shigenaga A; Tamura K; Dejima T; Ozawa M; Wakui H; Masuda S; Azuma K; Tsurumi-Ikeya Y; Mitsuhashi H; Okano Y; Kokuho T; Sugano T; Ishigami T; Toya Y; Uchino K; Tokita Y; Umemura S
    Nephron Clin Pract; 2009; 112(1):c31-40. PubMed ID: 19342867
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Angiotensin receptor blockers--significance for the therapy of hypertension].
    Magometschnigg D
    Wien Med Wochenschr; 2001; 151(7-8):153-6. PubMed ID: 11450162
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial: outcomes in patients receiving monotherapy.
    Julius S; Weber MA; Kjeldsen SE; McInnes GT; Zanchetti A; Brunner HR; Laragh J; Schork MA; Hua TA; Amerena J; Balazovjech I; Cassel G; Herczeg B; Koylan N; Magometschnigg D; Majahalme S; Martinez F; Oigman W; Seabra Gomes R; Zhu JR
    Hypertension; 2006 Sep; 48(3):385-91. PubMed ID: 16864741
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone.
    Waeber B; Aschwanden R; Sadecky L; Ferber P
    J Hypertens; 2001 Nov; 19(11):2097-104. PubMed ID: 11677377
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Angiotensin receptor blockers in congestive heart failure: evidence, concerns, and controversies.
    Bhatia V; Bhatia R; Mathew B
    Cardiol Rev; 2005; 13(6):297-303. PubMed ID: 16230887
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.
    Julius S; Kjeldsen SE; Weber M; Brunner HR; Ekman S; Hansson L; Hua T; Laragh J; McInnes GT; Mitchell L; Plat F; Schork A; Smith B; Zanchetti A;
    Lancet; 2004 Jun; 363(9426):2022-31. PubMed ID: 15207952
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Real-world effectiveness of valsartan on hypertension and total cardiovascular risk: review and implications of a translational research program.
    Abraham I; MacDonald K; Hermans C; Aerts A; Lee C; Brié H; Vancayzeele S
    Vasc Health Risk Manag; 2011; 7():209-35. PubMed ID: 21490947
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus.
    Yoneda T; Takeda Y; Usukura M; Oda N; Takata H; Yamamoto Y; Karashima S; Yamagishi M
    Am J Hypertens; 2007 Dec; 20(12):1329-33. PubMed ID: 18047925
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study.
    Ruilope LM; Malacco E; Khder Y; Kandra A; Bönner G; Heintz D
    Clin Ther; 2005 May; 27(5):578-87. PubMed ID: 15978306
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Effect of combination of valsartan with benazepril on blood pressure and left ventricular hypertrophy in SHR.
    Ke YS; Cao H; Yang T
    Acta Pharmacol Sin; 2000 Nov; 21(11):1043-7. PubMed ID: 11501062
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Additive effect of ACE inhibition and angiotensin II receptor blockade in type I diabetic patients with diabetic nephropathy.
    Jacobsen P; Andersen S; Jensen BR; Parving HH
    J Am Soc Nephrol; 2003 Apr; 14(4):992-9. PubMed ID: 12660333
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Valsartan: a novel angiotensin type 1 receptor antagonist.
    Thürmann PA
    Expert Opin Pharmacother; 2000 Jan; 1(2):337-50. PubMed ID: 11249553
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Angiotensin II receptor blockers--evidence along the cardiovascular continuum].
    Zeller A; Battegay E
    Praxis (Bern 1994); 2005 Apr; 94(15):581-94. PubMed ID: 15884724
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rationale and design of the KYOTO HEART study: effects of valsartan on morbidity and mortality in uncontrolled hypertensive patients with high risk of cardiovascular events.
    Sawada T; Takahashi T; Yamada H; Dahlöf B; Matsubara H;
    J Hum Hypertens; 2009 Mar; 23(3):188-95. PubMed ID: 18800142
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Proteinuria, chronic kidney disease, and the effect of an angiotensin receptor blocker in addition to an angiotensin-converting enzyme inhibitor in patients with moderate to severe heart failure.
    Anand IS; Bishu K; Rector TS; Ishani A; Kuskowski MA; Cohn JN
    Circulation; 2009 Oct; 120(16):1577-84. PubMed ID: 19805651
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Enhancing cardiac protection after myocardial infarction: rationale for newer clinical trials of angiotensin receptor blockers.
    Pfeffer MA
    Am Heart J; 2000 Jan; 139(1 Pt 2):S23-8. PubMed ID: 10618584
    [TBL] [Abstract][Full Text] [Related]  

  • 59. VALUE in hypertension treatment.
    Berk BC; Bisognano JD
    Curr Hypertens Rep; 2004 Dec; 6(6):411-3. PubMed ID: 15527682
    [No Abstract]   [Full Text] [Related]  

  • 60. [The significance of generic valsartan in the treatment of patients].
    Vértes A
    Lege Artis Med; 2011 Feb; 21(2):117-21. PubMed ID: 21710709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.